184 results
To evaluate the agreement between the results of four diagnostic tests for metal allergy (in vivo patch tests, resp. Lymfocyte Proliferation Test (LPT), a modified LPT (MELISA®), and the Lymfocyte Cytokine Production Test (LCPT), and the clinical…
1. To investigate whether the currently used hay fever forecast correlates with the symptoms that grass pollen allergic patients report directly using a new communication system that allows direct control, and whether the model can be improved.2.…
We want to verify if cinnamon (-derivatives) allergic patients do show dermatological reactions to cinnamon-derived UV protectors.
To evaluate the efficacy of HDM-SPIRE in the reduction of symptoms and the use of allergy rescue medication associated with HDM allergy in subjects with clinically relevant symptoms.
The primary objective of this study is to determine the eosinophil lifespans under inflammatory conditions in the blood and lungs of patients with eosinophilic asthma
The primary study objective is to assess the hypoallergenicity of an extensively hydroloyzed whey protein infant formula in children with cow's milk allergy.The second study objective is to assess the long-term effects on growth and tolerance…
Establishing an eliciting dose distribution for walnut on population level by determining individual eliciting doses in double-blind placebo controlled food challenges.
Multiple sensitizations were found using allergy tests, but most of the EoE patients have concurrent allergic diseases and the specific IgE found in serum apparently does not play a role in EoE pathogenesis. This theory is supported by the failure…
The aim of this pilot study is to validate potential biomarkers which diagnose patients who will benefit from asthma treatment with macrolide therapy by using non-invasively collected body fluid specimens. Th1/Th2/Th17 patterns in patients suffering…
Primary objectiveTo assess whether the use of alimemazine improves symptoms of allergic diseases and ADHD, as scored by the parents using standardized questionnaires (Sample Snap IV rating scales)
The objectives of the study are as follows:Primary:• Part 1: To assess the pharmacokinetics and relative bioavailability of three different formulations of PA101 (4% cromolyn sodium with and without mannitol, and 6% cromolyn sodium without mannitol…
Our primary objective is to compare the clinical outcome (time to and grade of symptom resolution) after 4-week-use of a whey based extensively hydrolysed formula (eHF) versus an amino acid-based formula (AAF) in children with nIgE-CMA. As secondary…
Objective: The main objective of our study is to examine whether we can use the IT (as determined by visual irritation grading scale after SLS patch test) to predict HS formation after reduction mammaplasties. The secondary objectives consist of…
Primary objective:1. To identify the components in human milk (e.g. nutrients, oligosaccharides, fatty acids and (pathogen specific) immunoglobulins) that have a protective effect against respiratory tract infections during the first year of life.…
Primary: To describe safety and tolerability during longer-term administration of AR101 and follow-up observation after the last dose of AR101.Secondary: - To assess the level of desensitization achievable through extended maintenance dosing of…
Determine the frequency, phenotype and function of disorder-related immune cells, or levels of immune molecules in skin and peripheral blood of patients with inflammatory skin diseases, during the active phase of disease prior to and/or at any time…
Primary: Is OIT with standard food products safe to perform in children aged 9 to 24 months with a proven food allergy for hen's egg, peanut, cow's milk, cashewnut, hazelnut, walnut and/or one of the more rare allergens (as soy, pits and…
To design an industry-sponsored surveillance study incorporating both additional and existing materials that has the possibility of identifying trends in the incidence of skin contact allergy.
The purpose of this Phase 3 study is to evaluate the safety and clinical efficacy of ligelizumab 240 mg and 120 mg given subcutaneously (s.c.) every 4 weeks (q4w) to ensure protection against allergic reaction by decreasing the sensitivity to oral…